Browse All

Current Filters

CLEAR FILTER x

TITLE

Serum Glial Fibrillary Acidic Protein compared with Neurofilament Light Chain as Biomarker for Multiple Sclerosis Disease Progression

Author:Meier, Stephanie   Benkert, Pascal   Maleska Maceski, Aleksandra   Schaedelin, Sabine   Oechtering, Johanna   Melie-Garcia, Lester   Cagol, Alessandro   Barakovic, Muhamed   Galbusera, Riccardo   Achtnichts, Lutz   Lalive, Patrice H.   Bridel, Claire   Müller, Stefanie   Pot, Caroline   Salmen, Anke   Disanto, Giulio   Zecca, Chiara   Abdelhak, Ahmed   Barro, Christian   Thebault, Simon   D’Souza, Marcus   Derfuss, Tobias   Orleth, Annette   Khalil, Michael   Yaldizli, Özguer   Hermesdorf, Marco   Wiendl, Heinz   Piehl, Fredrik   Fischer, Urs   Kappos, Ludwig   Gobbi, Claudio   Granziera, Cristina   Leppert, David   Willemse, Eline A.J.   Kuhle, Jens   

Session Name:P5: MS Prognosis/Epidemiology  

Topic:MS and Inflammatory Disease  

Program Number:P5.016  

Author Institution:Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  Translational Imaging in Neurology (ThINK) Basel, Department of Biomedical Engineering  Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland, Allschwill, Basel, Switzerland  Department of Neurology, Cantonal Hospital Aarau, Aarau, Switzerland, Aarau, Switzerland  Department of Clinical Neurosciences, Division of Neurology, Unit of Neuroimmunology, University Hospital of Geneva and Faculty of Medicine, Geneva, Switzerland, Geneva, Switzerland  Department of Neurology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland, St. Gallen, Switzerland  Service of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland, Lausanne, Switzerland  Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, Bern, Switzerland  Multiple Sclerosis Center (MSC), Department of Neurology, Neurocenter of Southern Switzerland  Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, Switzerland, Lugano, Switzerland  Weill Institute for Neurosciences, Department of Neurology, University of California at San Francisco (UCSF), San Francisco, California, USA, San Francisco, CA  Department of Neurology, Harvard Medical School, Boston, MA, USA, Boston, MA  Department of Medicine and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada, Ottowa, ON, Canada  Department of Neurology, Medical University of Graz, Graz, Austria, Graz, Austria  Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany, Münster, Germany  Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany, Muenster, Germany  Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden  Center for Neurology, Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden, Stockholm, Sweden  

Early Onset of Action and Sustained Efficacy of MRI Outcomes During Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis: Results of the 2-year MAGNIFY-MS Study

Author:De Stefano, Nicola   Achiron, Anat   Barkhof, Frederik   Chan, Andrew   Derfuss, Tobias   Hodgkinson, Suzanne   Leocani, Letizia   Montalban, Xavier   Prat, Alexandre   Schmierer, Klaus   Sellebjerg, Finn   Vermersch, Patrick   Wiendl, Heinz   Keller, Birgit   Smyk, Andrzej   Gardner, Lidia   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P6.018  

Author Institution:Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy  Multiple Sclerosis Center, Sheba Academic Medical Center, Ramat Gan, Israel  Department of Radiology, VU University Medical Center, Amsterdam, Netherlands  Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland  Department of Neurology, University Hospital Basel, Basel, Switzerland  Ingham Institute for Applied Medical Research, University of New South Wales Medicine, Sydney, Australia  Experimental Neurophysiology Unit, Vita-Salute San Raffaele University, Milan, Italy  Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain  Department of Neurosciences, Université de Montréal, Montreal, QC, Canada  The Blizard Institute, Centre for Neuroscience, Surgery & Trauma, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom  Danish MS Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark  Univ. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France  Department of Neurology, Institute of Translational Neurology, University of Münster, Muenster, Germany  the healthcare business of Merck KGaA, Darmstadt, Germany, Darmstadt, Germany  EMD Serono Research and Development Institute, Inc., Billerica, MA, USA , Billerica, MA  

Remibrutinib: A Novel BTKi in Development for MS With a Favorable Safety Profile in Various Autoimmune Disorders

Author:Williams, Mitzi   Airas, Laura   Chitnis, Tanuja   Saini, Sarbjit   Hide, Michihiro   Sussman, Gordon   Nakahara, Jin   Bermel, Robert   Dörner, Thomas   Loop, Brett   Ziehn, Marina   Willi, Roman   Kieseier, Bernd C.   Nikolaev, Ivan   Haemmerle, Sibylle   Zharkov, Artem   Siegel, Richard   Cenni, Bruno   Wiendl, Heinz   Maurer, Marcus   Giménez-Arnau, Ana   Montalban, Xavier   

Session Name:P7: MS Therapeutics 1  

Topic:MS and Inflammatory Disease  

Program Number:P7.015  

Author Institution:Joi Life Wellness Group, Atlanta, GA, USA, Atlanta, GA  Turku University Hospital and University, Finland, Turku, Finland  Brigham and Women's Hospital, Department of Neurology, Boston, MA, USA, Boston, MA  Johns Hopkins Asthma and Allergy Center, Baltimore, MD, USA, Baltimore, MD  Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan, Hiroshima, Japan  University of Toronto, Toronto, Ontario, Canada, Toronto, ON, Canada  Department of Neurology, Keio University School of Medicine, Tokyo, Japan, Shinjuku-ku, Japan  Mellen Center for MS, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  Department of Rheumatology and Clinical Immunology, Charite Universitätsmedizin Berlin  DRFZ, Berlin, Germany, Berlin, Germany  Novartis Pharmaceutical Corporation, Cambridge, MA, USA, Cambridge, MA  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Novartis Pharma AG, Basel, Switzerland  Department of Neurology, Heinrich-Heine University, Duesseldorf, Germany, Duesseldorf, Germany  Novartis Institutes for Biomedical Research, Basel, Switzerland, Basel, Switzerland  Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany, Muenster, Germany  Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany  Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany, Berlin, Germany  Department of Dermatology, Hospital del Mar - IMIM, Universitat Pompeu Fabra, Barcelona, Spain, Barcelona, Spain  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain, Barcelona, Spain